CohBar, Inc. (CWBR) News

CohBar, Inc. (CWBR)

Today's Latest Price: $2.49 USD

0.04 (-1.58%)

Updated Jun 1 4:00pm

Add CWBR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

Filter CWBR News Items

CWBR News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest CWBR News From Around the Web

Below are the latest news stories about CohBar Inc that investors may wish to consider to help them evaluate CWBR as an investment opportunity.

CohBar’s CEO to Participate on the New Breakthroughs in Aging Biology Panel at the BIO 2020 Digital Conference

CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced its Chief Executive Officer, Steven Engle will be a participant on the panel titled “Redefining What it Means to Get Old: New Breakthroughs in Aging Biology” at the BIO 2020 Digital Conference, to be held on June 8-12, 2020. The panel, featuring Nathaniel David, Co-Founder and President of Unity Biotechnology, Tom Hughes, CEO of Navitor Pharmaceuticals and Steven Engle, CEO of CohBar, will be moderated by Hannah Kuchler, US Pharma and Biotech Correspondent for the Financial Times.

Yahoo | May 27, 2020

CohBar Reports First Quarter 2020 Financial Results and Provides Business Update

MENLO PARK, Calif., May 14, 2020 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and.

Yahoo | May 14, 2020

CohBar’s Chief Operating Officer Jon Stern Plans to Step Down from Management Role

CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that Jon Stern plans to step down from his role as the company’s Chief Operating Officer, effective May 31, 2020. Since joining the company in 2012, Mr. Stern has served in various executive roles including Chief Strategic Officer and Chief Executive Officer.

Yahoo | May 13, 2020

CohBar To Target COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with its Apelin Receptor Agonist Peptides

CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that it has initiated testing of its CB5064 analogs in preclinical models of ARDS, to assess their potential as therapeutics for coronavirus disease 2019 (COVID-19) associated ARDS. In preclinical studies to date, these peptides have demonstrated the ability to activate the apelin receptor, a cell signaling pathway that published preclinical studies have shown can reduce the severity of acute lung injury by reducing lung fluid accumulation, hypoxemia, and cytokine secretion, which occur in COVID-19 associated ARDS, and lead to downstream injury to the kidney, heart, and other organs.

Yahoo | May 5, 2020

CohBar’s Abstract for the American Thoracic Society 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine

CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced its poster abstract for the  American Thoracic Society (ATS) 2020 International Conference was published in today’s edition of the American Journal of Respiratory and Critical Care Medicine. CohBar’s poster will contain data on a family of novel analogs of a peptide encoded in mitochondrial DNA, demonstrating beneficial effects in mouse models of Idiopathic Pulmonary Fibrosis (IPF).

Yahoo | May 1, 2020

CohBar to Announce 2020 First Quarter Financial Results and Provide Business Update on May 14, 2020

CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its first quarter 2020 financial results after the market closes on Thursday, May 14, 2020. Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company’s business.

Yahoo | April 30, 2020

Is CohBar, Inc. (NASDAQ:CWBR) A Volatile Stock?

Anyone researching CohBar, Inc. (NASDAQ:CWBR) might want to consider the historical volatility of the share price...

Yahoo | April 19, 2020

CohBar Announces Acceptance of Late Breaking Abstract on its Antifibrotic Peptides at The American Thoracic Society 2020 International Conference

CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced acceptance of a late-breaking abstract as a poster presentation at the American Thoracic Society (ATS) 2020 International Conference, which was scheduled to be held May 15-20 in Philadelphia, PA, and has since been cancelled. American Thoracic Society is currently exploring options for providing select elements of the conference content including ePosters in an online format later this year.

Yahoo | April 14, 2020

CohBar Provides Update on CB4211 Phase 1b Study for NASH and Obesity

CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that it is anticipating delays in the completion of its CB4211 Phase 1b study for NASH and obesity. This delay is a result of a pause by some of the company’s clinical research organization partners in all of their activities related to the study in response to the COVID-19 pandemic and the advice of the CDC and local authorities.

Yahoo | March 30, 2020

CohBar Reports Fourth Quarter 2019 Financial Results and Provides Business Update

MENLO PARK, Calif., March 12, 2020 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic.

Yahoo | March 12, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5587 seconds.